Product: Alkaline Phosphatase Antibody
Catalog: DF6225
Source: Rabbit
Application: WB, IHC, IF/ICC, ELISA(peptide)
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 57kD; 57kD(Calculated).
Uniprot: P05186
RRID: AB_2838191

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(88%), Bovine(88%), Horse(88%), Sheep(88%), Rabbit(100%), Dog(88%)
Clonality:
Polyclonal
Specificity:
ALPL Antibody detects endogenous levels of total ALPL.
RRID:
AB_2838191
Cite Format: Affinity Biosciences Cat# DF6225, RRID:AB_2838191.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

AKP2; Alkaline phosphatase liver/bone/kidney; Alkaline phosphatase liver/bone/kidney isozyme; Alkaline phosphatase tissue nonspecific isozyme; Alkaline phosphatase, tissue-nonspecific isozyme; Alkaline phosphomonoesterase; Alpl; AP TNAP; AP-TNAP; APTNAP; BAP; FLJ40094; FLJ93059; Glycerophosphatase; HOPS; Liver/bone/kidney type alkaline phosphatase; MGC161443; MGC167935; PHOA; PPBT_HUMAN; Tissue non specific alkaline phosphatase; Tissue nonspecific ALP; TNAP; TNSALP;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Description:
There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bone/kidney (tissue non-specific). The product of this gene is a membrane bound glycosylated enzyme that is not expressed in any particular tissue and is, therefore, referred to as the tissue-nonspecific form of the enzyme. Alkaline phosphatases form various dimers in vivo. This antibody can bind the four mentioned alkaline phosphatases.
Sequence:
MISPFLVLAIGTCLTNSLVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSAGSLAAGPLLLALALYPLSVLF

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Rabbit
100
Pig
88
Horse
88
Bovine
88
Sheep
88
Dog
88
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P05186 As Substrate

Site PTM Type Enzyme
T48 Phosphorylation
S110 Phosphorylation
T113 Phosphorylation
S131 Phosphorylation
S160 Phosphorylation
N430 N-Glycosylation

Research Backgrounds

Function:

This isozyme plays a key role in skeletal mineralization by regulating levels of diphosphate (PPi).

PTMs:

N-glycosylated.

Subcellular Location:

Cell membrane>Lipid-anchor.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Homodimer.

Family&Domains:

Belongs to the alkaline phosphatase family.

Research Fields

· Metabolism > Metabolism of cofactors and vitamins > Thiamine metabolism.

· Metabolism > Metabolism of cofactors and vitamins > Folate biosynthesis.

· Metabolism > Global and overview maps > Metabolic pathways.

References

1). Zeng Q et al. Glycyrrhizin micellar nanocarriers for topical delivery of baicalin to the hair follicles: a targeted approach tailored for alopecia treatment. Int J Pharm 2022 Aug 13;625:122109. (PubMed: 35973589) [IF=6.510]

2). Zheng S et al. Melatonin Accelerates Osteoporotic Bone Defect Repair by Promoting Osteogenesis–Angiogenesis Coupling. Front Endocrinol (Lausanne) 2022 Feb 22;13:826660. (PubMed: 35273570) [IF=6.055]

Application: WB    Species: Rat    Sample: BMSCs

Figure 1 Melatonin promoted the osteogenesis of BMSCs in vitro. (A) The effect of melatonin on BMSC proliferation measured by CCK-8 assays. (B, C) Images and quantification of ALP activity after 7 days of osteogenic induction (scale bars, 200 μm). (D, E) Calcium mineralization was assessed via ARS staining and quantification (scale bars, 200 μm). (F) mRNA expression levels of osteogenesis-related markers in BMSCs following treatment with/without melatonin. (G, H) Protein expression levels of osteogenesis-related markers (OCN, RUNX2, and ALP). (I, J) Immunofluorescent images of BMSCs stained for ALP and OCN (scale bars, 100 μm). All the experiments were repeated at least 3 times independently. CCK-8, cell counting kit-8; BMSCs, bone marrow mesenchymal stem cells; ARS, alizarin red S; ALP, alkaline phosphatase; OCN, osteocalcin; RUNX2, runt-related transcription factor 2. The data are presented as means ± SEM. * p < 0.05, ** p < 0.01 vs. control group, # p < 0.05, ## p < 0.01 vs. 100 nM melatonin group.

Application: IF/ICC    Species: Rat    Sample: BMSCs

Figure 1 Melatonin promoted the osteogenesis of BMSCs in vitro. (A) The effect of melatonin on BMSC proliferation measured by CCK-8 assays. (B, C) Images and quantification of ALP activity after 7 days of osteogenic induction (scale bars, 200 μm). (D, E) Calcium mineralization was assessed via ARS staining and quantification (scale bars, 200 μm). (F) mRNA expression levels of osteogenesis-related markers in BMSCs following treatment with/without melatonin. (G, H) Protein expression levels of osteogenesis-related markers (OCN, RUNX2, and ALP). (I, J) Immunofluorescent images of BMSCs stained for ALP and OCN (scale bars, 100 μm). All the experiments were repeated at least 3 times independently. CCK-8, cell counting kit-8; BMSCs, bone marrow mesenchymal stem cells; ARS, alizarin red S; ALP, alkaline phosphatase; OCN, osteocalcin; RUNX2, runt-related transcription factor 2. The data are presented as means ± SEM. * p < 0.05, ** p < 0.01 vs. control group, # p < 0.05, ## p < 0.01 vs. 100 nM melatonin group.

3). Kuang Z et al. Dopamine Suppresses Osteogenic Differentiation of Rat Bone Marrow-Derived Mesenchymal Stem Cells via AKT/GSK-3β/β-Catenin Signaling Pathway. Stem Cells Int 2022 Jun 29;2022:4154440. (PubMed: 35813889) [IF=5.131]

4). Liu H et al. Adipose-derived mesenchymal stromal cell-derived exosomes promote tendon healing by activating both SMAD1/5/9 and SMAD2/3. Stem Cell Res Ther 2021 Jun 10;12(1):338. (PubMed: 34112236) [IF=5.116]

Application: IHC    Species: rat    Sample: tendon

Fig. 5 |ADSC-Exos improved the healing of tendon injury. a, h The H&E staining of tendon injury at week 2 and week 4. b–f, i–m The expression of TNMD, collagen I, SCXA, ALP, and Runx2 were detected by immunohistochemistry assay at week 2 (n = 6) and week 4 (n = 6).

5). Chen J et al. Aspirin inhibits hypoxia-mediated lung cancer cell stemness and exosome function. Pathol Res Pract 2019 Mar 11 (PubMed: 30878308) [IF=3.309]

Application: WB    Species: human    Sample: A549 cells

Fig. 2.| Aspirin inhibits the hypoxia-enhanced stemness of A549 cells. (A–C) mRNA levels of SOX-2, OCT4, and ALDH1 were determined by qRT–PCR using specific primers, with GAPDH serving as the internal control. (D, E) mRNA levels of HIF-1α and COX-2 were determined by qRT–PCR using specific primers, with GAPDH serving as the internal control. (F) The concentration of PGE2 secreted by A549 cells was determined by ELISA. Each bar indicates the mean ± SD of n = 3 experiments. * indicates P < 0.05, ** indicates P < 0.01. (G) SOX-2, OCT4, ALDH1, HIF-1α, and COX-2 protein levels were determined by Western blot, with GAPDH serving as the loading control.

6). Song A et al. Cystathionine γ-lyase-H2S facilitates mandibular defect healing via inducing osteogenic differentiation of bone marrow mesenchymal stem cells. Arch Oral Biol 2020 Sep;117:104821. (PubMed: 32593877)

Application: IHC    Species: Mice    Sample:

Fig. 4. Immunohistochemistry stainings of RUNX2 and ALP in the mandibular defect area of WT, CSE−/−and CSE−/− + GYY4137 mice 2 weeks after surgery. WT and CSE−/− + GYY4137 mice demonstrated increased expression levels of RUNX2 and ALP in the defect area 2 weeks after surgery. Green arrows represent the margin of the mandibular defect area. WT: wild type; CSE-/-: CSE knock out mice; Runx2: runt-related transcription factor 2; ALP: alkaline phosphatase. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

7). Micro or nano: Evaluation of biosafety and biopotency of magnesium metal organic framework-74 with different particle sizes.

8). Delivery of therapeutic miRNA using Nanoscale Zeolitic Imidazolate Framework for accelerating vascularized bone regeneration.

9). Delivery of therapeutic miRNAs using nanoscale zeolitic imidazolate framework for accelerating vascularized bone regeneration.

10). Biomimetic hydroxyapatite coating on the 3D-printed bioactive porous composite ceramic scaffolds promoted osteogenic differentiation via PI3K/AKT/mTOR signaling pathways and facilitated bone regeneration in vivo.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.